Inhibition of carrageenan-induced expression of tissue and plasma prekallikreins mRNA by low level laser therapy in a rat paw edema model

• Published in: Revista brasileira de fisioterapia (São Carlos (São Paulo, Brazil)) Brazil)), 2011-02, Vol.15 (1), p.1-7
• Main Authors: Silva, M P, Bortone, F, Arauio, T R, Costa, MS, Silva, JA Jr
• Format: Article
• Language: por ; spa
• Subjects: Animal models; Salud
• ISSN: 1413-3555; 1809-9246

Background: Low level laser therapy (LLLT) has been used clinically in order to treat inflammation, where tissue and plasma prekallikrein have crucial importance. Plasma prekallikrein (PPK) is synthesized by the hepatocytes and secreted into the bloodstream, where it participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation and inflammation. Tissue prekallikrein is associated with important disease states (including cancer, inflammation, and neurodegeneration) and has been utilized or proposed as clinically important biomarker or therapeutic target of interest. Objective: To evaluate if LLLT modulates tissue and plasma prekallikreins mRNA expression in the carrageenan-induced rat paw edema. Methods: Experimental groups were assigned as followed: A sub(1) (Control-saline), A sub(2) (Carrageenan-only), A sub(3) (laser 660nm only) and A sub(4) (Carrageenan + laser 660nm). Edema was measured by a plethysmometer. Subplantar tissue was collected for the quantification of prekallikreins mRNA by Real time-Polymerase Chain Reaction. Results: A significantly decrease in the edema was observed after laser irradiation. Expression of prekallikreins increased after carrageenan injection. Tissue and plasma prekallikrein mRNA expression significantly decreased after LLLT's 660nm wavelength. Conclusion: These results suggest that expression of tissue and plasma prekallikreins is modulated by LLLT, which can be used in clinical practice due to its anti-inflammatory effects.Original Abstract: Contextualizacao: A laserterapia de baixa potencia tern sido usada para o tratamento de processos inflamatorios diversos em que a calicreina tecidual e a plasmatica possuem participagao ativa. A pre-calicreina plasmatica (PPK) e sintetizada pelos hepatocitos e secretada na corrente sangufnea, onde participa da ativagao da coagulacao, fibrinolise, geragao de cininas e inflamagao. A pre-calicreina tecidual esta associada com importantes doencas (incluindo cancer, inflamagao e neurodegeneracao) e tern sido utilizada ou sugerida clinicamente como importante biomarcador ou alvo terapeutico. Objetivo: Avaliar se a laserterapia altera a expressao genica da pre-calicreina tecidual e da plasmatica no modelo de inflamagSo aguda induzida pela carragenina. Metodos: Quarenta ratos foram separados em quatro grupos experimentais: A sub(1) (controle), A sub(2) (carragenina, apenas), A sub(3) (laser 660nm, apenas) e A sub(4) (Carragenina + laser 660nm). 0 edem